SCHEMBL370065

SCHEMBL370065

O=C(C=Cc1cc(Cl)ccc1Cl)c1ccc(=O)[nH]c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.50
MAPT P10636 7/20 0.44
LMNA P02545 5/20 0.44
KMT2A Q03164 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
MEN1 O00255 2/20 0.43
MAPK1 P28482 1/20 0.43
HSP90AA1 P07900 1/20 0.43
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 1/20 0.42
PKM P14618 1/20 0.42
MAOB P27338 3/20 0.41
GAA P10253 1/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2D6 P10635 2/20 0.40
HPGD P15428 2/20 0.40
PTPN5 P54829 1/20 0.40
ABCG2 Q9UNQ0 1/20 0.40
ATM Q13315 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL370064 1.00 EPHX2 (0.50) EPHX2MAPTLMNAKMT2AL3MBTL1
SCHEMBL368684 0.84 EPHX2 (0.45) EPHX2MAPTLMNAKMT2AL3MBTL1
SCHEMBL1390469 0.84 EPHX2 (0.45) EPHX2MAPTLMNAKMT2AL3MBTL1
SCHEMBL371063 0.84 EPHX2 (0.45) EPHX2MAPTLMNAKMT2AL3MBTL1
SCHEMBL368685 0.84 EPHX2 (0.45) EPHX2MAPTLMNAKMT2AL3MBTL1
SCHEMBL368622 0.80 MAOB (0.47) EPHX2MAOBCYP1A2CYP2D6ABCG2
SCHEMBL368621 0.80 MAOB (0.47) EPHX2MAOBCYP1A2CYP2D6ABCG2
SCHEMBL363722 0.77 DPP4 (0.55) MAPTLMNAKMT2AL3MBTL1MEN1
SCHEMBL9338441 0.74 MAPT (0.52) MAPTLMNAKMT2AMEN1MAPK1
SCHEMBL9338458 0.74 MAPT (0.52) MAPTLMNAKMT2AMEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593426-B1 1-HYDROXYIMINO-3-PHENYL-PROPANES HOFFMANN LA ROCHE (CH) 2014-08-20 EP disclosed
US-8765730-B2 1-hydroxyimino-3-phenyl-propanes Hoffmann-La Roche Inc (US) 2014-07-01 US disclosed
EP-2593426-A1 1-HYDROXYIMINO-3-PHENYL-PROPANES F.HOFFMANN-LA ROCHE AG (CH) 2013-05-22 EP disclosed
WO-2012007365-A1 1-HYDROXYIMINO-3-PHENYL-PROPANES F. HOFFMANN-LA ROCHE AG (CH) 2012-01-19 WO disclosed
US-20120010190-A1 1-HYDROXYIMINO-3-PHENYL-PROPANES F. HOFFMANN-LA ROCHE AG (CH) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010190-A1 1-HYDROXYIMINO-3-PHENYL-PROPANES GPBAR1, GPR119, ADRB1 EPHX2 1909/4885MAPT 4149/4885LMNA 2651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.